{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T01:51:04Z","timestamp":1775872264463,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,22]]},"DOI":"10.7759\/cureus.104091","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T07:10:37Z","timestamp":1771830637000},"source":"Crossref","is-referenced-by-count":1,"title":["Rifaximin-Induced Rhabdomyolysis"],"prefix":"10.7759","author":[{"given":"Samuel","family":"Acheampong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chidimma","family":"Udoyeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prince","family":"Darko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunice K","family":"Omeludike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/s0735-1097(02)02030-2","article-title":"ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins","volume":"40","author":"Pasternak RC","year":"2002","unstructured":"Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002, 40:567-72. 10.1016\/s0735-1097(02)02030-2","journal-title":"J Am Coll Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/tsaco-2021-000836","article-title":"Rhabdomyolysis: an American Association for the Surgery of Trauma Critical Care Committee clinical consensus document","volume":"7","author":"Kodadek L","year":"2022","unstructured":"Kodadek L, Carmichael Ii SP, Seshadri A, et al.. Rhabdomyolysis: an American Association for the Surgery of Trauma Critical Care Committee clinical consensus document. Trauma Surg Acute Care Open. 2022, 7:e000836. 10.1136\/tsaco-2021-000836","journal-title":"Trauma Surg Acute Care Open"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/cc2978","article-title":"Bench-to-bedside review: rhabdomyolysis - an overview for clinicians","volume":"9","author":"Huerta-Alard\u00edn AL","year":"2005","unstructured":"Huerta-Alard\u00edn AL, Varon J, Marik PE. Bench-to-bedside review: rhabdomyolysis - an overview for clinicians. Crit Care. 2005, 9:158-69. 10.1186\/cc2978","journal-title":"Crit Care"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2007.06.037","article-title":"The syndrome of rhabdomyolysis: complications and treatment","volume":"19","author":"Chatzizisis YS","year":"2008","unstructured":"Chatzizisis YS, Misirli G, Hatzitolios AI, Giannoglou GD. The syndrome of rhabdomyolysis: complications and treatment. Eur J Intern Med. 2008, 19:568-74. 10.1016\/j.ejim.2007.06.037","journal-title":"Eur J Intern Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31708","article-title":"The use of rifaximin in patients with cirrhosis","volume":"74","author":"Caraceni P","year":"2021","unstructured":"Caraceni P, Vargas V, Sol\u00e0 E, et al.. The use of rifaximin in patients with cirrhosis. Hepatology. 2021, 74:1660-73. 10.1002\/hep.31708","journal-title":"Hepatology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.14218\/JTG.2024.00048","article-title":"Long-term use of rifaximin in cirrhotic patients with hepatic encephalopathy: a mini review","volume":"3","author":"Li Y","year":"2025","unstructured":"Li Y, Jin K, Han Y, Lv L, Ding H. Long-term use of rifaximin in cirrhotic patients with hepatic encephalopathy: a mini review. J Transl Gastroenterol. 2025, 3:163-70. 10.14218\/JTG.2024.00048","journal-title":"J Transl Gastroenterol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.761192","article-title":"Rifaximin modulates the gut microbiota to prevent hepatic encephalopathy in liver cirrhosis without impacting the resistome","volume":"11","author":"Yu X","year":"2022","unstructured":"Yu X, Jin Y, Zhou W, et al.. Rifaximin modulates the gut microbiota to prevent hepatic encephalopathy in liver cirrhosis without impacting the resistome. Front Cell Infect Microbiol. 2022, 11:761192. 10.3389\/fcimb.2021.761192","journal-title":"Front Cell Infect Microbiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/ja.2014.106","article-title":"Rifaximin: beyond the traditional antibiotic activity","volume":"67","author":"Calanni F","year":"2014","unstructured":"Calanni F, Renzulli C, Barbanti M, Viscomi GC. Rifaximin: beyond the traditional antibiotic activity. J Antibiot (Tokyo). 2014, 67:667-70. 10.1038\/ja.2014.106","journal-title":"J Antibiot (Tokyo)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.03.027","article-title":"Rifaximin is largely safe and well tolerated but caution is necessary when taken with statins","volume":"12","author":"Cacciottolo TM","year":"2014","unstructured":"Cacciottolo TM, Kingdon A, Alexander GJ. Rifaximin is largely safe and well tolerated but caution is necessary when taken with statins. Clin Gastroenterol Hepatol. 2014, 12:1765. 10.1016\/j.cgh.2014.03.027","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30320-6","article-title":"Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"5","author":"Pose E","year":"2020","unstructured":"Pose E, Napoleone L, Amin A, et al.. Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Gastroenterol Hepatol. 2020, 5:31-41. 10.1016\/S2468-1253(19)30320-6","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.1583","article-title":"Rifaximin as a rare cause of rhabdomyolysis in cirrhosis","volume":"6","author":"Rezigh AB","year":"2018","unstructured":"Rezigh AB, Armenia E, Li T, Soesilo I. Rifaximin as a rare cause of rhabdomyolysis in cirrhosis. Clin Case Rep. 2018, 6:1296-9. 10.1002\/ccr3.1583","journal-title":"Clin Case Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/379087-rifaximin-induced-rhabdomyolysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T07:10:37Z","timestamp":1771830637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/379087-rifaximin-induced-rhabdomyolysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,22]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.104091","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,22]]}}}